Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | EMERALD-3: liver function trajectory & post-progression outcomes in eeHCC

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, iscusses post hoc exploratory analyses from the Phase III EMERALD-3 (NCT05301842) study of tremelimumab plus durvalumab (STRIDE), with or without lenvatinib, combined with transarterial chemoembolization (TACE) versus TACE alone in patients with embolization-eligible hepatocellular carcinoma (eeHCC). Liver function remained stable during treatment regardless of baseline status. STRIDE-based regimens showed favorable trends in survival and post-progression outcomes, including time to next treatment, across baseline liver function groups, with comparable safety. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Hello, everybody, and welcome to Madrid. It’s a great delight to present the update on the Emerald-3 in regard to disease progression trajectory and post-progression outcomes. If you recall, we presented at ASCO the outcome of the Emerald-3, which looked into adding on chemoembolization to the stride regimen, or tremelimumab map, and also looked into the potential for lenvatinib...

Hello, everybody, and welcome to Madrid. It’s a great delight to present the update on the Emerald-3 in regard to disease progression trajectory and post-progression outcomes. If you recall, we presented at ASCO the outcome of the Emerald-3, which looked into adding on chemoembolization to the stride regimen, or tremelimumab map, and also looked into the potential for lenvatinib. And we came out with a clinically meaningful outcome, improving PFS and OS for the stride plus days, and we’re waiting for the matured data as well. In that study, the ALBI score and Child-Pugh scoring were looked into and looked for clinical measures. We also looked into the time to next therapy or next treatment, TTNT. And in this analysis today at ESMO, we were able to find out that liver function remained stable over the treatment period with the stride plus-minus lenvatinib plus days, with a consistent pattern of subsequent anti-cancer therapy use, irrespective of baseline liver function. So, nearly all did not matter, which is great. Number two is stride plus-minus lenvatinib, again, plus days, showed clinically meaningful improvement in post-progression outcomes in regard to time to next treatment, and PFS2 after the first PFS with favorable overall survival outcome versus sorafenib, regardless of the baseline ALBI scoring either. And still importantly, the safety outcomes were broadly consistent with the overall study population, regardless of the baseline ALBI grading. One more thing, we hope that we’ll see you soon again to connect you with the mature data for the Emerald 3 study. Thanks for listening.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.